Alvotech Enrolls First Patient in Clinical Phase III Study Involving...
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® highconcentration 100mgmL product expected to be more convenient for patients compared to biosimilar competitors 400...
View ArticleMorphoSys Presents Results for Fiscal Year 2018 news with additional features
DGAPNews MorphoSys AG Key words Annual Results13.03.2019 2201 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany March 13 2019 MorphoSys Presents Results for...
View ArticleHuman medicines European public assessment report EPAR Zessly infliximab...
Human medicines European public assessment report EPAR Zessly infliximab Arthritis PsoriaticPsoriasisCrohn DiseaseArthritis RheumatoidColitis UlcerativeSpondylitis Ankylosing Date of authorisation...
View ArticlePeerReviewed Paper in Frontiers in Bioengineering and Biotechnology Reveals...
A recent study in Frontiers in Bioengineering and Biotechnology showed uBiome and its executives as top inventors in the microbiome industry.SAN FRANCISCO PRWEB March 18 2019 uBiome the leader in...
View ArticleSterna Biologicals holds Scientific Advisory Board meeting at 14th Congress...
DGAPNews sterna biologicals GmbH & Co. KG Key words Miscellaneous18.03.2019 1400 The issuer is solely responsible for the content of this announcement.STERNA BIOLOGICALS HOLDS SCIENTIFIC ADVISORY...
View ArticleFDA Approves Genentechs Tecentriq in Combination With Chemotherapy for the...
Tecentriq in combination with chemotherapy carboplatin and etoposide is the first and only cancer immunotherapy approved for the initial treatment of extensivestage small cell lung cancer ESSCLC First...
View ArticleSFA Therapeutics Wins Second Key U.S. Patent For Treatment of Chronic Liver...
Targets Liver Cancer SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program which utilizes microbiomederived metabolite small...
View ArticleOlder patients with Crohn's disease benefit from new medications
Wiley Combining medications that suppress the immune system has been successful in treating young patients with Crohn's disease but some physicians have been reluctant to use this strategy in older...
View ArticleCombined immunosuppression may be effective safe in treating older patients...
Combining medications that suppress the immune system has been successful in treating young patients with Crohn's disease but some physicians have been reluctant to use this strategy in older patients...
View ArticleLead Pharma Announces Start of Phase I Clinical Trials with SAR441169...
Sanofi Lead Pharmas collaborative partner in the development of SAR441169 successfully initiated first human dosing with this novel RORt Inverse Agonist candidate treatment For Lead Pharma this...
View ArticleHuman medicines European public assessment report EPAR Remicade infliximab...
Human medicines European public assessment report EPAR Remicade infliximab Spondylitis AnkylosingArthritis RheumatoidPsoriasisCrohn DiseaseArthritis PsoriaticColitis Ulcerative Date of authorisation...
View ArticleuBiome Awards Grant to The Australian National University to Study the...
The leader in microbial genomics awards grant to team of researchers at The Australian National University to investigate the relationship between mental illness and the gut microbiome.SAN FRANCISCO...
View ArticleCrohn's Disease Treatment Update
This article presents the American College of Gastroenterology's updated guidelines on managing Crohn's disease in adult patients. U.S. Pharmacist
View ArticleHuman medicines European public assessment report EPAR Hyrimoz adalimumab...
Human medicines European public assessment report EPAR Hyrimoz adalimumab Hidradenitis SuppurativaCrohn DiseaseArthritis Juvenile RheumatoidUveitisArthritis RheumatoidColitis UlcerativeSpondylitis...
View ArticleuBiome Awards Grant to Nnamdi Azikiwe University to Study the Influence of...
Researchers will use the grant to investigate the effect of probiotics on the urinary tract microbiome.SAN FRANCISCO PRWEB March 22 2019 uBiome has awarded microbiome research support in study design...
View ArticleMKSAP 49yearold woman with worsening joint symptoms
Test your medicine knowledge with theÂMKSAP challenge in partnership with theÂAmerican College of Physicians. A 49yearold woman is evaluated for recently worsening joint symptoms. She has a 13year...
View ArticleCelgene Submits Application to FDA for Ozanimod for the Treatment of...
Celgene Corporation NASDAQCELG today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration FDA for ozanimod for the treatment of adults with relapsing...
View ArticleMALADIE de CROHN Les propres cellules des patients la cl du traitement
Une technique qui utilise des cellules autologues modifies pour traiter la maladie de Crohn se rvle ici efficace avec cette recherche mene in vitro sur des cellules humaines. Un traitement suffisamment...
View ArticleNICE Issues Medtech Innovation Briefing on PredictSURE IBD for Inflammatory...
PredictImmune developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immunemediated diseases today announced that the UK's National Institute for...
View ArticleData Published in The Lancet Shows that CTP13 is Noninferior to Reference...
First of its kind study shows that CTP13 is comparable in efficacy safety and tolerability to reference infliximab in patients with active Crohns disease validating extrapolated approval data in this...
View Article